NASDAQ : LENZ
LENZ Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.05 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 95.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 95.83M |
| Enterprise Value | -123.60M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 28, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 31.42M |
| Shares Outstanding | 31.42M |
| Shares Change (YoY) | +12.13% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 2.65% |
| Owned by Institutions (%) | 66.39% |
| Float | 18.39M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.75 |
| Forward PS | 3.74 |
| PB Ratio | 0.44 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.55 |
| Quick Ratio | 12.91 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -59.21% |
| Return on Assets (ROA) | -37.36% |
| Return on Invested Capital (ROIC) | -45.12% |
| Return on Capital Employed (ROCE) | -61.84% |
| Weighted Average Cost of Capital (WACC) | 13.68% |
| Revenue Per Employee | $81,309 |
| Profits Per Employee | -$922,836 |
| Employee Count | 152 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 5,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.73 |
| 52-Week Price Change | -90.05% |
| 50-Day Moving Average | 4.07 |
| 200-Day Moving Average | 8.02 |
| Relative Strength Index (RSI) | 35.74 |
| Average Volume (20 Days) | 1,037,615 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 9.10M |
| Short Previous Month | 10.56M |
| Short % of Shares Out | 28.95% |
| Short % of Float | 49.45% |
| Short Ratio (days to cover) | 11.70 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 12.36M |
| Gross Profit | 10.13M |
| Operating Income | -149.69M |
| Pretax Income | -140.27M |
| Net Income | -140.27M |
| EBITDA | -149.25M |
| EBIT | -149.69M |
| Loss Per Share | -$4.48 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 220.00M |
| Total Debt | 569,000 |
| Net Cash | 219.43M |
| Net Cash Per Share | $6.98 |
| Equity (Book Value) | 219.26M |
| Book Value Per Share | 6.98 |
| Working Capital | 216.07M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -113.91M |
| Capital Expenditures | -511,000 |
| Depreciation & Amortization | 437,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -114.42M |
| FCF Per Share | -$3.64 |
Margins
| Measure | Value |
|---|
| Gross Margin | 81.97% |
| Operating Margin | -1,211.17% |
| Pretax Margin | -1,134.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.13% |
| Shareholder Yield | -12.13% |
| Earnings Yield | -146.88% |
| FCF Yield | -119.40% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $15.00 |
| Price Target Difference | 391.80% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 63.99% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |